logo

Zymeworks Inc. (ZYME)



Trade ZYME now with
  Date
  Headline
1/12/2020 10:06:41 AM Zymeworks Announces Deal With Pfizer And Initiation Of Phase 2 Trial Evaluating ZW25 In Combination With Ibrance
10/28/2019 8:37:20 AM Zymeworks Reports Phase 1 Data For ZW25 In Combination With Chemotherapy In Advanced Gastroesophageal Adenocarcinoma
10/16/2019 4:23:16 PM Zymeworks Appoints Kathryn O’Driscoll As Chief People Officer
9/17/2019 6:57:32 AM Zymeworks Names Lota Zoth Chair Of Board; To Voluntarily Delist From TSX
6/19/2019 9:35:07 PM Zymeworks Announces Pricing Of $175.0 Mln Public Offering
5/29/2019 6:55:41 AM Zymeworks To Get $2.0 Mln In Connection With Merck’s Completion Of Preclinical Study For Bispecific Antibody Candidate
4/15/2019 6:49:20 AM Zymeworks Initiates Multicenter Phase 2 Clinical Trial On ZW25
1/17/2019 5:03:10 PM Zymeworks Reports Second IND-Submission Milestone Achieved In Lilly Collaboration
11/27/2018 6:34:36 AM Zymeworks And BeiGene Announce License Deal For Zymeworks’ HER2-Targeted Therapeutic Candidates, ZW25 And ZW49
10/23/2018 8:55:40 AM Zymeworks, LEO Pharma Enter Bispecific Antibody Licensing And Research Collaboration
10/23/2018 6:50:00 AM Zymeworks And LEO Pharma A/S Enter Licensing And Research Collaboration
8/1/2018 8:07:50 AM Zymeworks Q2 Revenue $22.0 Mln Vs. $1.3 Mln Prior Year
6/11/2018 9:37:12 AM Zymeworks Closes Public Offering Of 6.21 Mln Shares
  
 
>